Soligenix invited by BARDA to submit $25M contract proposal for Ebola/Marburg vaccines

SOLIGENIX, INC.

BARDA invites Soligenix to submit full contract proposal for SuVax and MarVax vaccines.
Program valued up to $25M over 5 years for SuVax Phase 1 studies, with options for MarVax.
SuVax demonstrated 100% protection in non-human primate model with 3-dose series.
No protective vaccines currently available for Sudan ebolavirus or Marburg marburgvirus.
Contract award not guaranteed; requires favorable technical review and negotiation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.